Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Lopez-Rios

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Plos One|January 18, 2013
Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenibFernando Lopez-Rios, Barbara Angulo, Belen Gomez, et al.
Cancer Letters|June 20, 2014
A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyondCarlos Gomez-Martín, Fernando Lopez-Rios, Jorge Aparicio, et al.
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
ESMO Open|September 25, 2018
ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?Florian Cabillic, Paul Hofman, Marius Ilie, et al.
Journal of Clinical Pathology|February 7, 2013
Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancerFernando Lopez-Rios, Barbara Angulo, Belen Gomez, et al.
Histopathology|November 13, 2023
Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologistsKeith M Kerr, Lukas Bubendorf, Fernando Lopez-Rios, et al.
Molecular Cancer Therapeutics|June 11, 2009
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenograftsWells A Messersmith, N V Rajeshkumar, Aik Choon Tan, et al.
BMC Cancer|November 14, 2012
PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcomePurificacion Estevez-Garcia, Angel Castaño, Ana C Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2015
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT TrialManuel Hidalgo, Carlos Plaza, Monica Musteanu, et al.
Ebiomedicine|March 2, 2020
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacyÁlvaro Quintanal-Villalonga, Irene Ferrer, Elizabeth Guruceaga, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Plos One|January 18, 2013
Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenibFernando Lopez-Rios, Barbara Angulo, Belen Gomez, et al.
Cancer Letters|June 20, 2014
A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyondCarlos Gomez-Martín, Fernando Lopez-Rios, Jorge Aparicio, et al.
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
ESMO Open|September 25, 2018
ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?Florian Cabillic, Paul Hofman, Marius Ilie, et al.
Journal of Clinical Pathology|February 7, 2013
Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancerFernando Lopez-Rios, Barbara Angulo, Belen Gomez, et al.
Histopathology|November 13, 2023
Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologistsKeith M Kerr, Lukas Bubendorf, Fernando Lopez-Rios, et al.
Molecular Cancer Therapeutics|June 11, 2009
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenograftsWells A Messersmith, N V Rajeshkumar, Aik Choon Tan, et al.
BMC Cancer|November 14, 2012
PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcomePurificacion Estevez-Garcia, Angel Castaño, Ana C Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2015
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT TrialManuel Hidalgo, Carlos Plaza, Monica Musteanu, et al.
Ebiomedicine|March 2, 2020
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacyÁlvaro Quintanal-Villalonga, Irene Ferrer, Elizabeth Guruceaga, et al.
Pageof 7